Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

Phase 3

Conditions: Brow Ptosis
Facial Scarring

Interventions: Drug: Normal Saline Flush, 0.9% Injectable Solution
Drug: 5-Fluorouracil

First Posted Date: 2017-07-17

Last Posted Date: 2018-07-26

Lead Sponsor: Eyelid and Facial Consultants

Target Recruit Count: 50

Registration Number: NCT03219580

Locations: 🇺🇸
Eyelid and Facial Consultants, New Orleans, Louisiana, United States
🇺🇸
Leonard J. Chabert Medical Center, Houma, Louisiana, United States

Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Apatinib
Drug: 5-fluorouracil

First Posted Date: 2017-07-06

Last Posted Date: 2017-07-06

Lead Sponsor: Hui ting Xu，MD

Target Recruit Count: 42

Registration Number: NCT03210064

Locations: 🇨🇳
Hui ting Xu, Wuhan, Hubei, China

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: CMAB009
Drug: Irinotecan
Drug: Folinic acid
Drug: 5-fluorouracil

First Posted Date: 2017-07-02

Last Posted Date: 2024-11-07

Lead Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd

Target Recruit Count: 520

Registration Number: NCT03206151

Locations: 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳
Tianjing medical university cancer institute and hospital, Tianjin, Tianjin, China

Combination Chemotherapy and Bevacizumab with the NovoTTF-100L(P) System in Treating Participants with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Phase 1

Recruiting

Conditions: Refractory Malignant Neoplasm
Colorectal Carcinoma Metastatic in the Liver
Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm in the Liver

Interventions: Biological: Bevacizumab
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Fluorouracil
Drug: Temsirolimus
Drug: Leucovorin
Drug: Oxaliplatin
Procedure: Tumor Treating Fields Therapy

First Posted Date: 2017-06-29

Last Posted Date: 2024-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT03203525

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase 1

Withdrawn

Conditions: Ovarian Cancer

Interventions: Biological: Avelumab
Biological: Bevacizumab
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: 5-fluorouracil
Drug: Fulvestrant
Drug: Leucovorin
Drug: Paclitaxel
Drug: omega-3 acid ethyl esters
Drug: Oxaliplatin
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6301
Biological: haNK®

First Posted Date: 2017-06-23

Last Posted Date: 2021-03-18

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03197584

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1

Active, not recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Nab-Paclitaxel
Drug: Gemcitabine
Drug: Cobimetinib
Drug: PEGPH20
Drug: BL-8040
Drug: RO6874281
Drug: Atezolizumab
Drug: Oxaliplatin
Drug: Bevacizumab
Drug: AB928
Drug: Tocilizumab
Drug: Tiragolumab
Drug: Leucovorin
Drug: Selicrelumab
Drug: Fluorouracil

First Posted Date: 2017-06-20

Last Posted Date: 2024-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 340

Registration Number: NCT03193190

Locations: 🇺🇸
Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 24 locations

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Phase 3

Completed

Conditions: Esophageal Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: 5-FU

First Posted Date: 2017-06-16

Last Posted Date: 2024-10-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 749

Registration Number: NCT03189719

Locations: 🇿🇦
The Medical Oncology Centre of Rosebank ( Site 2506), Johannesburg, Gauteng, South Africa
🇪🇸
Hospital Universitario Central de Asturias ( Site 0708), Oviedo, Asturias, Spain
🇺🇸
University of Maryland Medical Center ( Site 0013), Baltimore, Maryland, United States

and more 186 locations

Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Cancer

Interventions: Radiation: Radiotherapy
Drug: Cisplatin
Drug: 5-FU

First Posted Date: 2017-06-05

Last Posted Date: 2017-06-05

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 263

Registration Number: NCT03175939

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1

Withdrawn

Conditions: Triple Negative Breast Cancer

Interventions: Biological: avelumab
Biological: bevacizumab
Drug: capecitabine
Drug: cisplatin
Drug: cyclophosphamide
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: nab-paclitaxel
Drug: Lovaza
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK

First Posted Date: 2017-06-05

Last Posted Date: 2021-03-18

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03175666

A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer

Phase 2

Conditions: Pancreatic Cancer

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2017-05-25

Last Posted Date: 2017-08-29

Lead Sponsor: Petr Kavan

Target Recruit Count: 20

Registration Number: NCT03167112

Locations: 🇨🇦
Jewish General Hospital, Montréal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy